MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S.

The average age of men who get diagnosed is 67.

Many patients with metastatic cancers receive therapy that is initially highly effective, often resulting in complete remission. However, cancer cells have a remarkable capacity to evolve resistance ...

When PSA rises after surgery, PSMA PET/CT detects cancer missed by conventional imaging ...

Studies on whether pelvic lymph node dissection (PLND) provides a survival benefit in men with prostate cancer having surgery ...

Scientists report landmark "evolutionary double-bind" strategy to overcome treatment resistance in prostate cancer.

The Prostate Cancer Foundation (PCF) today announced a $10 million unrestricted gift from an anonymous donor to launch a ...

Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated “classic” neurovascular bundle patterns and over 96% showed more than ...

Actinium-225 is a targeted and highly-potent alpha emitter that holds promise for patients who do not respond to lutetium-177 ...

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and providers in The Beam, published monthly.